Pros and cons: Should allergen immunotherapy be considered in all patients with allergic asthma
| Autor: | Ronald Dahl, Roy Gerth van Wijk |
|---|---|
| Přispěvatelé: | Internal Medicine |
| Jazyk: | angličtina |
| Rok vydání: | 2022 |
| Předmět: |
House dust mite
Allergen immunotherapy medicine.medical_specialty Allergy biology business.industry Immunology Allergic asthma Disease asthma medicine.disease biology.organism_classification allergy Gina guidelines Dermatology sublingual immunotherapy respiratory tract diseases immune system diseases subcutaneous immunotherapy medicine Subcutaneous immunotherapy allergen immunotherapy Immunology and Allergy business Asthma |
| Zdroj: | Allergy: European Journal of Allergy and Clinical Immunology, 77(3), 1070-1072. Wiley-Blackwell Publishing Ltd Gerth van Wijk, R & Dahl, R 2022, ' Pros and cons : Should allergen immunotherapy be considered in all patients with allergic asthma? ', Allergy, vol. 77, no. 3, pp. 1070-1072 . https://doi.org/10.1111/all.15123 |
| ISSN: | 0105-4538 |
| DOI: | 10.1111/all.15123 |
| Popis: | Allergen immunotherapy (AIT) has gained a permanent place in the therapeutic arsenal for the patient with allergy. Particularly, substantial evidence has been established for the efficacy of AIT in allergic rhinitis. A hallmark of AIT is it disease modifying effect resulting in persistent benefit after the treatment has been terminated. Both the subcutaneous and sublingual mode of administration appear to be safe. It is, however, a matter of debate whether AIT can be implemented for patients with asthma. EAACI and GINA guidelines recommend sublingual AIT in house dust mite driven asthma. The question however remains whether the different available forms of AIT should be used for allergic asthma in general. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text